Xylo Technologies (Xylo Technologies) Debt-to-Equity : 0.42 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Xylo Technologies Debt-to-Equity?

Xylo Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $9.08 Mil. Xylo Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.70 Mil. Xylo Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $23.58 Mil. Xylo Technologies's debt to equity for the quarter that ended in Dec. 2023 was 0.42.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Xylo Technologies's Debt-to-Equity or its related term are showing as below:

XYLO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.03 Max: 0.42
Current: 0.42

During the past 12 years, the highest Debt-to-Equity Ratio of Xylo Technologies was 0.42. The lowest was 0.01. And the median was 0.03.

XYLO's Debt-to-Equity is ranked worse than
68.21% of 711 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs XYLO: 0.42

Xylo Technologies Debt-to-Equity Historical Data

The historical data trend for Xylo Technologies's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xylo Technologies Debt-to-Equity Chart

Xylo Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.01

0.03

0.26

0.42

Xylo Technologies Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.03	0.32	0.26	0.37	0.42

Competitive Comparison of Xylo Technologies's Debt-to-Equity

For the Medical Devices subindustry, Xylo Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xylo Technologies's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xylo Technologies's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Xylo Technologies's Debt-to-Equity falls into.

Xylo Technologies Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Xylo Technologies's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(9.084	+	0.702)	/	23.576
	=	0.42

Xylo Technologies's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(9.084	+	0.702)	/	23.576
	=	0.42

Xylo Technologies (NAS:XYLO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Xylo Technologies Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Xylo Technologies's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Xylo Technologies (Xylo Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xylo Technologies Ltd (NAS:XYLO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

2QM0:Germany

Address

10 Hanechoshet Street, 4th Floor, Tel Aviv, ISR, 6971072

Website

https://www.medigus.com

Medigus Ltd is an Israel-based medical device company. It is engaged in the development, manufacturing, and marketing of surgical endostaplers and direct vision systems for minimally invasive medical procedures. The key product of the company is the MUSE (Medigus Ultrasonic Surgical Endostapler) system is a single-use device for the incisionless treatment of GERD (gastroesophageal reflux disease), which is based on proprietary platform technology and know-how. The company also develops a range of micro video cameras under the micro ScoutCam portfolio of products. It operates in five segments: Medical, E-Commerce, Online, Electric Vehicles, and Corporate. The company's geographical segments include the United States, United Kingdom, Germany, Israel, China, and Others.